ADMA Biologics (ADMA) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ADMA Biologics (ADMA) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 29.7% versus a loss of 40.7%. ADMA Biologics is the larger company by market cap ($2.32 billion vs $2.07 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | MLYS |
|---|---|---|
| Share price | $10.36 | $23.37 |
| Market cap | $2.32B | $2.07B |
| 1-day change | +0.29% | +4.42% |
| YTD return | -43.20% | -35.60% |
| 1-year return | -29.72% | -40.67% |
| 5-year return | +839.09% | — |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | — |
| Revenue growth (YoY) | +19.63% | — |
| Net income (latest FY) | $146.93M | $-154.65M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | — |
| Net margin | 28.80% | — |
| 52-week high | $20.46 | $47.65 |
| 52-week low | $7.21 | $21.46 |
| Distance from 52-week high | -49.36% | -50.95% |
| Analyst consensus | none | none |
| Avg. price target upside | +64.09% | +107.53% |
| Average volume | 2.66M | 1.04M |
| Shares outstanding | 223.98M | 88.41M |
| Employees | 640 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADMA has outperformed MLYS by 11.0 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Healthcare · Biotechnology · 640 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Healthcare · Biotechnology · 76 employees
ADMA vs MLYS FAQ
Which is bigger, ADMA Biologics or Mineralys Therapeutics?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.32B compared with $2.07B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, ADMA or MLYS?
ADMA returned -29.72% over the past 12 months, compared with -40.67% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.